BioTelemetry (BEAT) Looks Good: Stock Adds 7.7% in Session
BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks · 09/14 13:27
BioTelemetry cheers Needham's Buy initiation
Needham initiated BioTelemtry ([[BEAT]] +6.0%) with a Buy rating, price target of $52, indicating upside of 33% from current levels.Analyst David Saxon says that sales mix shift in Healthcare, the
Seekingalpha · 09/11 17:34
Calculating The Fair Value Of BioTelemetry, Inc. (NASDAQ:BEAT)
Today we will run through one way of estimating the intrinsic value of BioTelemetry, Inc. (NASDAQ:BEAT) by estimating...
Simply Wall St. · 09/07 12:20
Benzinga's Top Upgrades, Downgrades For September 2, 2020
Upgrades * For Zillow Group Inc (NASDAQ: ZG), Deutsche Bank upgraded the previous rating of Hold to the current rating Buy. In the second quarter, Zillow Gr showed an EPS of $0.41, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $88.82 and a 52-week-low of
Benzinga · 09/02 15:20
BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates
BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 23:50
BioTelemetry inks sales agent agreement with Boston Scientific
Boston Scientific (BSX -3.1%) has announced a sales agent agreement with BioTelemetry (BEAT +6.1%), for BSX's LUX-Dx Insertable Cardiac Monitor (ICM) Syste
seekingalpha · 07/30 20:15
BioTelemetry Q2 EPS $0.35 Beats $0.16 Estimate, Sales $89.41M Miss $89.52M Estimate
BioTelemetry (NASDAQ:BEAT) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.16 by 118.75 percent. This is a 33.96 percent decrease over earnings of $0.53 per share from the
Benzinga · 07/30 20:07
BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results
Posts Strong Results and Ramps Up Business Development ActivityMALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of l
GlobeNewswire · 07/30 20:05
BioTelemetry Earlier Reported Sales Agent Deal With Boston Scientific For LUX-Dx Insertable Cardiac Monitor System, No Terms Disclosed
Benzinga · 07/30 12:57
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
BioTelemetry, Inc. Announces Sales Agent Agreement with Boston Scientific Corporation
Company expands portfolio of solutions with groundbreaking insertable cardiac monitor systemMALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health inform
GlobeNewswire · 07/30 11:00
BioTelemetry's (BEAT) CEO Joseph Capper on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/30 04:00
BioTelemetry EPS beats by $0.08, beats on revenue
Seeking Alpha · 07/30 04:00
BioTelemetry Q2 Earnings Preview
BioTelemetry (NASDAQ:BEAT) is scheduled to announce Q2 earnings results on Thursday, July 30th, after market close. The consensus EPS Estimate is -$0.02 an
seekingalpha · 07/30 02:35
BioTelemetry, Inc. Acquires Remote Patient Monitoring Platform from Centene Subsidiary
Expands relationship to serve Centene membersMALVERN, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cos
GlobeNewswire · 07/29 12:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
BioTelemetry, Inc. to Release Second Quarter 2020 Earnings Results on July 30, 2020
MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2020 earnings on Thursday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thurs
GlobeNewswire · 07/23 20:05
Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
Investor's Business Daily · 07/10 14:00
65 Biggest Movers From Yesterday
Gainers MOGU Inc. (NASDAQ: MOGU) shares climbed 104.8% to close at $5.92 on Tuesday.
Benzinga · 07/08 10:05
Is BioTelemetry, Inc. (BEAT) A Good Stock To Buy?
Insider Monkey · 07/05 19:45
Webull provides a variety of real-time BEAT stock news. You can receive the latest news about BioTelemetry through multiple platforms. This information may help you make smarter investment decisions.
About BEAT
BioTelemetry, Inc. provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized laboratory services for clinical research. The Company operates in three segments: Healthcare, Technology and Research. The Healthcare segment, operating as CardioNet, LLC and Heartcare Corporation of America, Inc., is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Research segment, operating as Cardiocore, LLC and VirtualScopics, Inc., is engaged in laboratory services that provide cardiac monitoring, imaging services, scientific consulting and data management services for drug, medical treatment and device trials. The Technology segment, operating as Braemar Manufacturing, LLC, Universal Medical, Inc. and BioTelemetry Belgium BVBA. and BioTelemetry Technology ApS, focuses on the manufacturing, engineering and development of noninvasive cardiac monitors for healthcare companies.